[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know",
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=a5e21f564e52caed4a2fffab589c30f6e9c7999ba5a48e54a5d2888ff2f21615",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735080619,
      "headline": "Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know",
      "id": 132140562,
      "image": "https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=a5e21f564e52caed4a2fffab589c30f6e9c7999ba5a48e54a5d2888ff2f21615"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corporation (TM) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks BK Technologies Corporation (BKTI) and Servotronics, Inc. (SVT).",
    "url": "https://finnhub.io/api/news?id=6d26057dc5b9439eb8123a50f4a0c738667580e1ef7139f38f0ce43637fcf5a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735069320,
      "headline": "Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals",
      "id": 132136766,
      "image": "https://media.zenfs.com/en/zacks.com/234b27bba87616a250ccab2b188f127a",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corporation (TM) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks BK Technologies Corporation (BKTI) and Servotronics, Inc. (SVT).",
      "url": "https://finnhub.io/api/news?id=6d26057dc5b9439eb8123a50f4a0c738667580e1ef7139f38f0ce43637fcf5a6"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",
    "summary": "Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=51197698ba61a8094b1c6d7f875e1f0b4caf463b6c1edbd4b52e1177af56e909",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735058520,
      "headline": "Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",
      "id": 132148889,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=51197698ba61a8094b1c6d7f875e1f0b4caf463b6c1edbd4b52e1177af56e909"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist",
    "summary": "Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy rating on the shares. The firm moderates its view of the odds of success of suzetrigine in chronic pain to 30% from 60% after “disappointing” Phase 2 results in lumbosacral radiculopathy. The early approval of vanza triple, or Alyftrek, is “positive, but was largely expected,” adds the analyst, who sees upside from pipeline updates in 2025. Published first on TheFly – the ul",
    "url": "https://finnhub.io/api/news?id=54a0ce77807228f886171394568ae959bb87e30b82e66118e2f342c22c05db82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735051832,
      "headline": "Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist",
      "id": 132131918,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy rating on the shares. The firm moderates its view of the odds of success of suzetrigine in chronic pain to 30% from 60% after “disappointing” Phase 2 results in lumbosacral radiculopathy. The early approval of vanza triple, or Alyftrek, is “positive, but was largely expected,” adds the analyst, who sees upside from pipeline updates in 2025. Published first on TheFly – the ul",
      "url": "https://finnhub.io/api/news?id=54a0ce77807228f886171394568ae959bb87e30b82e66118e2f342c22c05db82"
    }
  },
  {
    "ts": null,
    "headline": "3 No-Brainer Stocks to Buy on the Latest Sell-Off",
    "summary": "Warren Buffett's mentor Benjamin Graham once said, \"In the short run, the market is a voting machine but in the long run, it is a weighing machine.\"  Graham also knew, though, that business fundamentals matter over the long term.  In fact, the temporary pullbacks make them even better choices because the stocks are available at more attractive prices.",
    "url": "https://finnhub.io/api/news?id=b50ae7e79bf00d9355c1609c402bc4911a2db6088a595e46a5efcc3d4f470799",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735035900,
      "headline": "3 No-Brainer Stocks to Buy on the Latest Sell-Off",
      "id": 132129785,
      "image": "https://g.foolcdn.com/editorial/images/801947/stock-chart-falling-with-man-holding-hand-to-head.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Warren Buffett's mentor Benjamin Graham once said, \"In the short run, the market is a voting machine but in the long run, it is a weighing machine.\"  Graham also knew, though, that business fundamentals matter over the long term.  In fact, the temporary pullbacks make them even better choices because the stocks are available at more attractive prices.",
      "url": "https://finnhub.io/api/news?id=b50ae7e79bf00d9355c1609c402bc4911a2db6088a595e46a5efcc3d4f470799"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘Their Painkiller Equaled The Placebo. And That’s Just A Shame’",
    "summary": "We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. The Federal Reserve created quite a bit of turmoil in the […]",
    "url": "https://finnhub.io/api/news?id=41f2635e773a057af45f94d8dec9ed4e1557b5167975fda338caacf24e059fd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735028344,
      "headline": "Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘Their Painkiller Equaled The Placebo. And That’s Just A Shame’",
      "id": 132129312,
      "image": "https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. The Federal Reserve created quite a bit of turmoil in the […]",
      "url": "https://finnhub.io/api/news?id=41f2635e773a057af45f94d8dec9ed4e1557b5167975fda338caacf24e059fd9"
    }
  }
]